Committed to the Future of Antibiotics

7 December 2017

Meet our CEO at JPM 2018 to discuss DAV132

Our CEO, Florence Séjourné will be attending JPM (...)

29 November 2017

In support of November C. diff Awareness Month Da Volterra announces complete QOL survey recruitment

In support of November proclaimed as “C. difficile (...)

16 November 2017

Da Volterra is a partner in the new COMBACTE-CDI consortium

Da Volterra is proud to join academic and EFPIA partners in the (...)

16 November 2017

Da Volterra is a signatory of the BEAM Alliance position paper

As part of our ongoing commitment to combating antibiotic (...)

Who we are

Da Volterra:
Committed to the Future of Antibiotics

Da Volterra is a biotechnology company developing a portfolio of unique products in the antibacterial field, with a specific focus on antibiotic resistance.

Our most advanced product is DAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. Discover DAV132 in the video below:

DAV132 has already undergone three phase I clinical trials. It has been developed using in-house expertise on resistant gut microbiomes and proprietary drug delivery technologies. Learn more >

500,000 Americans infected
by Clostridium difficile
each year

Learn more >


Developpeur PHP Drupal